Skip to main content

Nonprofit · EIN 65-1230251

CANARY FUND

Also known as CANARY FOUNDATION

Tax-exempt · WOODSIDE, CA 94062

Financials

$1.9M$1.4M2023$1.8M$1.7M2024$2.2M$2.2M2025
Revenue Expenses · by fiscal year end
Financials of CANARY FUND by year, from its e-filed returns
Year endedFormRevenueExpensesNet incomeTotal assetsLiabilitiesNet assets
December 31, 2025990$2,205,595$2,185,417$20,178$2,450,031$707,828$1,742,203
December 31, 2024990$1,792,816$1,727,013$65,803$1,850,228$115,382$1,734,846
December 31, 2023990$1,883,312$1,352,591$530,721$1,687,918$23,683$1,664,235
Financial details: 990 for the year ended December 31, 2025

Revenue

Contributions, gifts and grants
$2,163,219
Program service revenue
$0
Investment income
$42,376
Other revenue
$0

Expenses

Grants and similar amounts paid
$1,760,069
Compensation of officers, directors and key employees
$0
Other salaries and wages
$174,975
Salaries, compensation and benefits (total)
$297,850
Professional fundraising fees
$0
Depreciation
$12,326
Program services (functional)
$2,011,373
Management and general (functional)
$103,525
Fundraising (functional)
$70,519

Balance sheet and other

Total assets, start of year
$1,850,228
Total assets, end of year
$2,450,031
Total liabilities, end of year
$707,828
Net assets, end of year
$1,742,203
Land, buildings and equipment
$21,925
Net assets without donor restrictions
$838,357
Net assets with donor restrictions
$903,846
Gross receipts
$2,205,595
Employees
3
Year formed
2004
State of legal domicile
CA

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990 for the year ended December 31, 2025, highest compensation first.

NameTitleHours / weekCompensation
Heidi AumanProgram Manager40$201,750
Don ListwinFounder & CEO
Trustee or director, Officer
8$0
Kevin KennedyTreasurer
Trustee or director, Officer
4$0
Michael BallDirector
Trustee or director
4$0
Dale JantzenDirector
Trustee or director
4$0
Hilary ValentineDirector
Trustee or director
4$0
990 for the year ended December 31, 2024: 6 people
NameTitleHours / weekCompensation
Heidi AumanProgram Manager40$180,600
Don ListwinFounder & CEO
Trustee or director, Officer
8$0
Kevin KennedyTreasurer
Trustee or director, Officer
4$0
Michael BallDirector
Trustee or director
4$0
Dale JantzenDirector
Trustee or director
4$0
Hilary ValentineDirector
Trustee or director
4$0
990 for the year ended December 31, 2023: 6 people
NameTitleHours / weekCompensationOther / benefits
Heidi AumanProgram Manager40$168,000$22,500
Don ListwinFounder & CEO
Trustee or director, Officer
8$0$0
Kevin KennedyTreasurer
Trustee or director, Officer
4$0$0
Michael BallDirector
Trustee or director
4$0$0
Dale JantzenDirector
Trustee or director
4$0$0
Hilary ValentineDirector
Trustee or director
4$0$0

Address and contacts

Address (IRS master file)
PO BOX 620134, WOODSIDE, CA 94062-0134
In care of
% MARY MURILLO
Principal officer (990 for 2025)
Don Listwin, PO Box 620134, Woodside, CA 940629991
Signed the 990
Don Listwin, Founder & CEO
Phone
(650) 646-3200
Return prepared by
REGALIA BERGER & BERGER CPAS

California records

California keeps its own records of charities and corporations. Search them by EIN 65-1230251 or by the name CANARY FUND.

Attorney General, Registry of Charities and Fundraisers
Registration status and filed reports (CT-TR-1, RRF-1)

Mission

Canary Foundation is a public charity exempt from U.S. federal income tax under Section 501(c)(3) of the Internal Revenue Code in the United States. Canary Foundation of Canada is a Public Foundation registered with the Canada Revenue Agency; Business Number 82906 8550 RROOO1.The Canary Foundation has assembled teams of cancer researchers recognized by their peers as leaders in their disciplines from across multiple institutions and disciplines to attack the problem of early detection in a new, collaborative, action-oriented manner with the foremost objective of translating research into clinical applications. Canary differentiators include: * Dedication to early detection * Leaders in collaborative science * Focused and managed research * Best-in-class talent * 100% of donations goes to researchOne of the first decisions the Science Team made was to choose ovarian cancer as a prototype for creating an early detection blood test to detect trace amounts of proteins called biomarkers pro

990 for the year ended December 31, 2025

Program accomplishments

  • The goal of the Canary Scientific Programs is to develop blood tests and imaging tests that can together be used to detect lethal cancers at a curable stage. Our plan for early and accurate cancer detection involves first screening patients with a blood test and then moving those patients who tested positive to a high-resolution imaging test to further isolate cancer so that it can be removed. Chances of survival are highest when cancer is detected before it spreads. Thus, accurate detection of cancer that would otherwise be lethal at its earliest stage promises to dramatically improve survival after diagnosis. Canary has supported research programs focused on solid tumor cancer types including ovarian, lung, pancreas and prostate cancers, as well as a Collaborations Program with collaborating early detection programs and centers that include the Canary Center at Stanford for Cancer Early Detection.
    Expenses $2,011,373 · grants $1,760,069
  • Canary Ovarian Cancer Program: The goal of our ovarian research program is to develop a strategy to accurately identify ovarian cancers that would otherwise be lethal at a stage when they are readily curable. The program focuses on high grade serous ovarian cancer, which is the most common and lethal subtype, in order to have the highest impact on reducing ovarian cancer mortality. Our aims include understanding the earliest stages of cancer development in the fallopian tube, identifying molecular markers for early detection or prevention, and developing advanced imaging techniques for early detection of the disease. Development of blood and imaging tests follows a similar roadmap; both include biomarker discovery followed by validation, but they also involve different techniques and challenges.
  • Canary Lung Cancer Program:Canary is focused on developing diagnostics with high sensitivity and specificity to detect otherwise lethal lung cancers at a stage when they are readily curable. To this end, Canary has assembled a team of experts who are collaborating to discover and validate biomarkers for blood and imaging tests that together will identify individuals harboring lethal lung cancers so that they can be removed. The Canary Lung Cancer Program has supported the development and maintenance of critical biospecimen resources, blood biomarker discovery and validation, molecular imaging projects for early detection of lethal lung cancer, and epidemiology and modeling for effective lung cancer screening.(continued Sch O)
  • Canary Prostate Cancer Program:The specific goals of the Canary Foundation Prostate program are to develop tests that can: 1) Identify lethal prostate cancers at an early (curable) stage; 2) Classify prostate cancers as either 1) potentially lethal; best treated with aggressive therapy b) non-lethal: suitable for continued monitoring without aggressive treatment. Given the large body of published but invalidated candidate markers for prostate cancer, we are focusing our initial efforts on evaluating the performance of a selected set of promising biomarkers. Candidate biomarkers are evaluated based on their ability to detect lethal prostate cancers at an early (curable) stage and to discriminate lethal from non-lethal prostate cancer. We are considering both fluid-based and tissue-based biomarkers for prognostic applications. The Canary Prostate Active Surveillance Study (PASS) enrolls men who opt for active surveillance of their early stage prostate cancer. Men are followed closely for signs of cancer progression, donating biospecimens and clinical data for a minimum of 5 years or until receiving treatment for their disease. The biospecimens and clinical data provide a valuable resource to test promising biomarkers and predictive tools for their use in the active surveillance setting.Canary Pancreatic Cancer Program:Canary is focused on developing diagnostics with high sensitivity and specificity to detect otherwise lethal pancreatic cancers at an early stage when they can be cured through surgical resection. We anticipate that no single biomarker will be sufficient to create a test with the required sensitivity and specificity to detect pancreatic cancer early. Instead, a definitive diagnosis will rely upon combinations of biomarkers and upon blood and imaging tests used together. To this end, the Canary pancreatic cancer researchers have collaborated to discover and validate biomarkers that will provide the basis for blood and imaging tests for the early detection of pancreatic cancer. Canary Collaborations Program:Canary Foundation believes that a collaborative, coordinated approach is necessary to achieve our goals. Our multi-disciplinary, multi-institutional Early Detection Program provides a great example of this philosophy in action. Our foundation partnerships link mutual scientific expertise and entrepreneurial spirit in the hopes of advancing research in the diagnostic arena of early cancer detection. We partner with research institutions, foundations, industry and government organizations. Collaborating programs include the Canary Center at Stanford and the CRUK Cambridge Centre Early Detection Programme at the University of Cambridge in England. We provide scientific program management to make sure that all funded research activities among the scientists and clinicians at the various partner institutions are on track and that any obstacles are rapidly addressed and overcome.

What it must file and when

IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.

Tax yearYear endedDueIRS public records
2025December 31, 2025May 15, 2026990 on file
2024December 31, 2024May 15, 2025990 on file
2023December 31, 2023May 15, 2024990 on file

IRS record

EIN
65-1230251
Tax-exempt status
501(c)(3): Charitable, religious, educational or scientific organization
Foundation status
Publicly supported organization (170(b)(1)(A)(vi))
Donations deductible (Pub 78)
Public charity, 50% deduction limit
Exempt since
2005
Accounting year ends
December
Files
Form 990 or 990-EZ
Assets (IRS master file)
$2,450,031
Income (IRS master file)
$2,205,595

Filing history

FormYear endedRevenueExpensesAssetsReturn
990December 2025$2,205,595$2,185,417$2,450,031XML
990December 2024$1,792,816$1,727,013$1,850,228IRS
990December 2023$1,883,312$1,352,591$1,687,918XML
990December 2022$2,494,481$1,374,478$1,170,913IRS
990December 2021–––IRS
990December 2020–––IRS
990December 2019–––IRS
990December 2018–––IRS

990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 65-1230251).

Questions about CANARY FUND

What is the EIN of CANARY FUND?
The employer identification number (EIN) of CANARY FUND is 65-1230251.
Is CANARY FUND tax-exempt?
Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2005.
Are donations to CANARY FUND tax-deductible?
Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
Which annual return does CANARY FUND file?
Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
When is the next return of CANARY FUND due?
The return for tax year 2026 (the year ending December 31, 2026) is due May 17, 2027. Form 8868 extends it by six months; the 990-N cannot be extended.
When did CANARY FUND last file with the IRS?
The latest return in the IRS public files is the 990 for the year ended December 2025.
Who is the principal officer of CANARY FUND?
The 990 for the year ended December 31, 2025 names Don Listwin.
Who are the officers and directors of CANARY FUND?
The 990 for the year ended December 31, 2025 lists 6 people; 1 received compensation from the organization, the highest $201,750 (Heidi Auman, Program Manager).
How much revenue does CANARY FUND have?
On its 990 for the year ended December 31, 2025 it reported revenue of $2,205,595, expenses of $2,185,417 and total assets of $2,450,031 at year end.

Other nonprofits in WOODSIDE

All nonprofits in WOODSIDE · California · Philanthropy, voluntarism and grantmaking foundations